Drug Search Results
More Filters [+]

Motexafin

Alternative Names: motexafin
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Motexafin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer

Phase 2: Glioblastoma|Glioma|Non-Small-Cell Lung Cancer|Multiple Myeloma|Lymphoma, Non-Hodgkin|Gliosarcoma|Brain Cancer|Melanoma|Breast Cancer|Chronic Lymphoid Leukemia|Renal Cell Carcinoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Adenocarcinoma|Brain Stem Cancer

Phase 1: Oligodendroglioma|Glioblastoma|Astrocytoma|Breast Cancer|Prostate Cancer|Glioma|Myelodysplastic-Myeloproliferative Diseases|Intestinal Diseases|Lymphoma|Colorectal Cancer|Rectal Diseases|Multiple Myeloma|Plasmacytoma|Head and Neck Cancer|Laryngeal Cancer|Prostatic Diseases|Intestinal Cancer|Oropharyngeal Cancer|Non-Small-Cell Lung Cancer|Myeloproliferative Disorders|Breast Diseases|Bronchogenic Carcinoma|Gastrointestinal Cancer|Leukemia, Plasma Cell|Squamous Cell Carcinoma|Lung Cancer|Hypopharyngeal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A6701QIBA

N/A

Unknown status

Prostate Cancer

2022-12-01

NCI-2009-01092

P2

Completed

Gliosarcoma|Glioblastoma

2011-02-16

NCI-2012-01829

P2

Completed

Glioma

2010-04-01

PCYC-0222

P2

Terminated

Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia

2010-02-01

Recent News Events